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Adenosine suppresses immune responses through the A2A receptor (A2AR). This study investigated the interleukin 10 (IL-10)
genetic profile and the expression of A2AR in peripheral blood mononuclear cells (PBMCs) of patients with mild cognitive
impairment (MCI), Alzheimer disease (AD), and age-matched controls to verify, if they may help distinguish diﬀerent forms
of cognitive decline. We analyzed the IL-10 genotype and the expression of A2AR in 41 subjects with AD, 10 with amnestic MCI
(a-MCI), 49 with multiple cognitive domain MCI (mcd-MCI), and 46 controls. There was a significant linear increase in A2AR
mRNA levels and A2AR density from mcd-MCI to a-MCI, with intermediate levels being found in AD. The IL-10 AA genotype
frequency was 67% in a-MCI, 46% in AD, 35% in mcd-MCI, and 20% in controls. These data suggest that the assessment of the
IL-10 genotype and the expression of A2AR in PBMCs may be a valuable means of diﬀerentiating between a-MCI and mcd-MCI.
1. Introduction
The purine ribonucleoside adenosine (Ado) is a natu-
rally occurring metabolite that is ubiquitously distributed
throughout the body as a metabolic intermediary. Ado accu-
mulates in the extracellular space at the site of inflammation
[1] in response to metabolic stress and cell damage, and
there is evidence that it could play a key role in preserving
homeostasis [2]. The physiological responses to Ado take
place as a result of the binding and activation of diﬀerent
transmembrane receptors: high-aﬃnity A1 receptor (A1R)
and A2AR, low-aﬃnity A2BR, or low-abundance A3R. A2AR
are found throughout the body, and an increasing wealth
of evidence supports the idea that they represent the major
immunoregulatory arm of the Ado receptor system, down-
regulating inflammation [3–7] and also preventing beta
amyloid (Aβ) induced synaptotoxicity [8].
A recent study showed that stimulation of A2AR repre-
sents a crucial second signal in the production of IL-10, the
major anti-inflammatory cytokine [9].
Inflammation is accepted to be a feature of Alzheimer’s
disease (AD) [10, 11] and the pathogenesis of neurodegen-
eration has been at least in part attributed to the release of
proinflammatory cytokines from brain resident cells [12, 13]
and, although less consistently, from peripheral cells [14, 15].
Recently, specific risk sets of pro-inflammatory and anti-
inflammatory alleles were found to be associated with AD
at diﬀerent ages of onset [16]. Such alleles also comprise the
−1082 polymorphism (G/A substitution) in the IL-10 gene
promoter region [17]. On the basis of these considerations,
we investigated (1) the expression of the A2AR gene and A2AR
protein levels in the peripheral blood mononuclear cells
(PBMCs) of patients with mild cognitive impairment (MCI,
the preclinical state of dementia), patients with outright AD
and age-matched controls without cognitive impairment and
(2) the relationship between the IL-10 genetic profile and the
A2A phenotype, since A2AR regulates IL-10 production.
2. Materials and Methods
2.1. Study Design. The study involved 41 AD patients (mean
age 79.47 ± 6.30 years), 46 non demented age- and gender-
matched healthy controls with similar educational levels
(mean age 79.98 ± 6.36 years), and 59 subjects with MCI
(mean age 78 ± 5.16 years). All of the patients were
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Caucasians living in Northern Italy who were prospectively
enrolled from a larger population of outpatients attending
the Geriatric Unit of the Ospedale Maggiore IRCCS, Univer-
sity of Milan, Italy.
Probable AD was diagnosed using standard clinical
procedures and DMS IV and NINCDS-ADRDA criteria [18].
Functional status was assessed by means of the Activities of
Daily Living (ADL) and Instrumental Activities of Daily Liv-
ing (IADL) scales and cognitive performance bymeans of the
Mini-Mental State Examination (MMSE) and of an extensive
neuropsychological evaluation. A computed tomography or
magnetic resonance imaging scan corroborated the diagnosis
of AD.
The criteria for the diagnosis of normal cognition were as
follows: (1) no active neurological or psychiatric disorder; (2)
no ongoing medical problems or related treatments interfer-
ing with cognitive function; (3) a normal neurological exam;
(4) no psychoactive medications; (5) the ability to live and
function independently in the community.
The MCI subjects were divided into two groups on
the basis of their cognitive characteristics: amnestic MCI
(a-MCI, 10 patients) and multiple cognitive domain MCI
(mcd-MCI, 49 patients). The a-MCI subjects met the cri-
teria described by Petersen [19]: only memory impairment
(>1.5 SD above age- and education-specific norms) with
no diﬃculties in any other area of cognitive functioning.
The mcd-MCI subjects were impaired in at least two
cognitive domains (>1 SD below the mean of an age- and
education-matched population), their cognitive decline was
self-reported or reported by a reliable informant, but they
could not be diagnosed as having dementia. The cutoﬀ score
of 1 SD (less than the threshold used for a-MCI) was selected
in order to ensure greater diagnostic sensitivity, albeit at
the expense of diagnostic specificity. In fact the presence
of more than one cognitive deficit and frequent initial
IADL impairment may lead to mcd-MCI being mistaken for
dementia, and the less restrictive criterion of >1 SD allows
their better diﬀerentiation [20].
Blood from all patients and controls was collected in the
morning between 8 and 9AM, after a 6-hour fast.
None of the patients or controls was on treatment
with dipyridamole or methylxanthines, and their caﬀeine
consumption was about 80mg/die (one cup of coﬀee) or less.
The risk of possible inflammatory processes was mini-
mized by the fact that none of the subjects selected showed
any clinical signs of inflammation (their body temperature
was normal, and none of them had a concomitant inflam-
matory condition) and that they all had normal plasma
albumin, transferring, and C-reactive protein levels. All of
the subjects and their relatives gave their informed consent,
and the study protocol was approved by the University
Hospital’s Ethics Committee.
2.2. Apolipoprotein E (ApoE) Genotyping. Whole blood was
collected by means of a venipuncture into Vacutainers
(Becton Dickinson Co., Rutherford, NJ). Genomic DNA was
extracted using a previously described salting-out method
[21], and its concentration and purity were determined by
means of spectrophotometric analysis. The ApoE genotypes
were determined by means of the PCR amplification of
a 234 base-pair fragment of exon 4 of the ApoE gene,
followed by digestion using Cfo1, as previously described
[22]. Restriction patterns were revealed by means of 4%
agarose gel electrophoresis.
2.3. Cytokine Genotyping. A polymerase chain reaction-
sequence-specific primers (PCR-SSP) method was employed
to assess IL-10 genotypes. The sequence in the promoter
region of the IL-10 (polymorphism −1082) gene was
amplified using the cytokine genotyping tray method (One
Lambda, Canoga Park, CA, USA); the human β-globin gene
was amplified as an internal control for the genomic DNA
preparation. PCR conditions were indicated by the One
Lambda PCR program (OLI-1), and the PCR products were
visualized by electrophoresis in 2.5% agarose gel.
2.4. A2AR mRNA Expression. PBMCs were separated by
density gradient using the Lympholyte-H kit (Cedarlane
Laboratories Limited, Canada), and total RNA was isolated
from 15 × 106 frozen cells using Chomczynski and Sacchi’s
modified method [23]. The concentration of total RNA
was quantified by means of spectrophotometry, and 2 ug
of RNA were reverse-transcribed using the M-MLV Reverse
Transcriptase System and oligo (dT) (Clontech, Italy). The
resulting cDNA was real-time amplified in a final volume of
50 μL. The mix contained 25 μL of 2x iQ SYBR Green Super-
mix (dNTPs, iTaq, and MgCl2; Bio-Rad, Italy) and 300mM
of each primer (A2AR: Forward 5′-GGCTGCCCCTACACA-
TCATC-3′, Reverse 5′-GCCAGGTACATGAGCCAGAGA-
3′). PCR was performed using a Chromo 4 instrument and
analyzed using Opticon Monitor 2 (Celbio, Italy). All of the
reactions were performed in duplicate, with thermal cycling
conditions of 10min at 95◦C followed by 40 cycles at 95◦C for
15 s, 56◦C for 40 s, and 72C◦ for 30 s, with a ramp of 5C◦/s.
Real-time PCR for glyceraldehyde-3-phosphate dehydroge-
nase (GAPDH) was performed simultaneously (GAPDH:
Forward 5′-ATTCCACCCATGGCAAATTC3′, Reverse 5′-
TGGGATTTCCATTGATGACAAG-3′).
The relative quantification of A2A mRNA expression was
carried out by using the comparative cycle threshold (Ct)
method and the formula normalization ratio (NR) = 2−ΔΔCt.
The ΔCt value of each sample was calculated as the Ct of
the target gene minus the Ct of GAPDH, and then the ΔΔCt
value was obtained as the diﬀerence between the ΔCt of the
sample and the ΔCt of the calibrator [24]. According to this
formula, the normalization ratio of the calibrator in each run
is 1. The calibrator in each sample run was the same RNA
extracted from a single healthy control and stored at −80◦C.
2.5. A2A Receptor Densities. PBMCs from 10 a-MCI, 27
AD, 20mcd-MCI, and 20 controls subjects were available
for protein expression. The cells were lyzed in Triton X-
114 Tris buﬀer with a protease inhibitors cocktail (Sigma,
Italy). Briefly, after centrifugation (12,000 rpm at 4◦C), the
supernatant was loaded onto a sucrose cushion buﬀer and
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Figure 1: A2AR mRNA levels (mean values ± standard error) in
PBMCs from 41AD, 10 a-MCI, 49mcd-MCI, and 46 control (CT)
subjects quantified by the 2−ΔΔCt method. Bonferroni post hoc: a-
MCI versus controls and mcd-MCI patients (P < .05).
incubated at 37◦C for 3min. The samples were then cen-
trifuged again in order to obtain two phases, and 10 μg of the
total protein extracts of the aqueous phase were denatured by
boiling for 10min at 100◦C in Laemmli SDS loading buﬀer,
reduced with 5% mercaptoethanol and separated by 10%
SDS polyacrylamide gel [25]. Electrophoresis was performed
at 20–30mA for 110min, and the proteins were blotted onto
a 0.45 μm polyvinylidene fluoride membrane (Immobilon,
Millipore, Italy) at 90 V for 90min at 4◦C; after transfer,
nonspecific binding was blocked for 120min using 5% milk
in phosphate buﬀer saline with 0.1% Tween 20 (PBST). The
membranes were incubated overnight with polyclonal rabbit
antihuman A2AR antibody (1 : 2000) (Calbiochem, Ger-
many) and goat antirabbit IgG HRP (1 : 2000) (Bio-Sciences,
Italy) and chemiluminescent substrate (Bio-Sciences, Italy).
Purified A2AR (Chemicon, Italy) was loaded as positive
control (onemajor band of about 45 kDa) and to evaluate the
interassay variability (less than 10% in all experiments). To
account for protein loading variation [26], the membranes
were stripped and then reprobed with monoclonal anti-
human GAPDH (1 : 8000) (Chemicon International, USA)
and rabbit antimouse IgG-HRP (1 : 8000) (Sigma, Italy) and
chemiluminescent substrate. All experiments were run in
duplicate. Membranes were scanned, and the density of
the protein bands was estimated by IM1D software (Bio-
Sciences, Italy). The results were expressed as Arbitrary Units
(A2AR /GAPDH ratio).
2.6. Statistical Analysis. The statistical analysis was per-
formed using the SPSS statistical package (SPSS version
17, Chicago, IL). An outlier analysis was conducted before
the comparisons. The diﬀerences in mRNA and protein
levels, expressed as mean values ± standard error (SE),
were calculated using the one-way analysis of variance
followed by Bonferroni’s post hoc test in the case of multiple
comparisons. The genotype and allele distributions were
evaluated using Pearson’s χ2. A P value <.05 was considered
statistically significant.
3. Results
3.1. Distribution of the ApoE Genotype. The frequency of
ApoE ε4 was 50% in a-MCI patients, 44% in AD patients,
38.8% in mcd-MCI patients, and 11% in control subjects.
These frequencies are similar to those already reported [27].
3.2. Distribution of the IL-10 Genotype. The distribution
of the −1082 (G/A) polymorphism was similar to that
previously described [22]. In particular, the frequency of the
AA genotype, associated with a higher risk of AD, was 67% in
a-MCI, 46% in AD, 35% in mcd-MCI, and 20% in controls,
respectively (P = .014).
3.3. A2A Gene Expression and Receptor Densities. The qPCR
analysis (Figure 1) revealed significantly higher (P < .05)
A2AR mRNA levels in patients with a-MCI (3.77 ± 1.02)
than in controls (2.12 ± 0.21) and in patients with mcd-
MCI (1.42 ± 0.12). It is interesting to note that also A2AR
density (Figures 2 and 3), expressed as A2AR/GAPDH ratio,
was significantly higher in patients with a-MCI (0.71± 0.17)
than in controls (0.62 ± 0.05) and in patients with mcd-
MCI (0.43 ± 0.05). Both gene expression (2.50 ± 0.22) and
density (0.50 ± 0.06) of the A2AR in PBMCs of AD patients
were not significantly diﬀerent from those of the controls
(Figures 1 and 3). When the data were stratified according
to the presence or absence of the ApoE ε4 allele, A2AR gene
expression and receptor density were similar both in the ε4
carriers and noncarriers.
Interestingly, the carriers of the G allele of the −1082
IL-10 polymorphism (GG and GA) showed the lowest level
of A2AR mRNA, independently of cognitive status (1.7 ±
0.13 and 2.7 ± 0.36, in carriers versus noncarriers, resp.;
P = .002).
4. Discussion
The results of this observational study show that the level
of A2AR expression is higher in PBMCs from a-MCI than
from mcd-MCI. When the data were stratified according to
the presence or absence of the ApoE ε4 allele, A2AR gene
expression and receptor density were similar both in the ε4
carriers and noncarriers. This indicates that the ApoE ε4
allele, a major genetic risk factor for late onset sporadic AD
[28–30], does not appear to participate in the modulation of
this gene.
The small number of patients and the lack of A2AR
measurements in the cerebrospinal fluid do not allow us to
draw any conclusion on the relationship between peripheral
A2AR modulation and Ado metabolism in the brain. Yet the
finding of an upregulation of A2AR in the PBMCs of subjects
with a-MCI but not with AD seems to fit with the results of a
previous study [31] demonstrating that in the brain cortex
the increased expression of both A2AR and A1R is mainly
an early event in the pathogenesis of AD [32]. One possible
explanation of our finding is that a second event, which
is required for the development of AD in a-MCI subjects,
subsequently intervenes to downregulate A2AR expression
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Figure 2: Paradigmatic example of the Western blot analysis of the A2AR densities in PBMC extract from one subject belonging to the AD,
a-MCI, mcd-MCI, or control (CT) group, run in duplicate.
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Figure 3: A2AR densities (mean values± standard error) in PBMCs
from 27AD, 10 a-MCI, 20mcd-MCI, and 20 control (CT) subjects
expressed as A2AR/GAPDH ratio. Bonferroni post hoc: a-MCI
versus controls and mcd-MCI patients (P < .05).
in PBMCs by a negative feedback mechanism and thus
counteracts the anti-inflammatory eﬀect of Ado. Therefore,
within the multifactorial pathogenesis of AD, there may be a
specific time-window for the involvement of the Ado system.
It is still unclear whether and how peripheral inflamma-
tion acts on the AD brain; there are, however, several lines of
evidence in favour of its contribution to the disease process.
First, AD patients who also have short-term peripheral
infections undergo a sudden decline in cognitive status
[33]; second, plasma levels of alpha1-antichymotrypsin,
interleukin-6, and C-reactive protein are increased before the
clinical onset of various types of dementia, including AD
[34]; third, the signs of inflammation observed in the brain
of AD patients are comparable to those seen in peripheral
inflammatory reactions and are likely to have a strong
cytotoxic eﬀect on neurons [35]; fourth, individuals who
have levels of Aβ and tau aggregates similar to those of AD
patients, but yet do not develop dementia, exhibit lesser signs
of inflammation [36].
The lack of a significant diﬀerence in A2AR expression
between AD subjects and controls is consistent with the data
of former studies showing that also cytokine production
is increased in PBMCs of MCI but not AD subjects [15,
37]. Thus, a peripheral inflammatory response seems to be
involved only in the early stage of the disease and appears to
be lost in overt AD.
In our patients the IL-10 low-producer AA genotype,
which also seemed to be associated with the highest mRNA
levels of A2AR, was more frequent in the a-MCI group. IL-
10, a powerful anti-inflammatory cytokine, maps to chro-
mosome 1 between 1q31 and 1q32, is highly polymorphic,
and its production is correlated to biallelic polymorphisms
at position−1082 (G to A). In previous studies, we not
only described a significantly greater prevalence of the IL-
10 −1082 AA low-producer genotype in subjects with overt
AD as well as in subjects with a-MCI who eventually
progressed to AD [37], but we also found a reduced IL-
10 generation in PBMCs from these patients after Aβ
stimulation [22]. Interestingly a report on centenarians, in
whom an exceptionally long lifespan is held to reflect the
combined influence of lifestyle choices and genetic factors,
demonstrated that longevity is significantly associated with
the IL-10 high-producer GG genotype [38].
Limitations of this observational study are the small
number of enrolled subjects, and that it was possible to
evaluate the correlation between the IL-10 genetic profile
and gene expression only for A2AR. However, if the findings
of this study are confirmed by a prospective study with a
larger number of subjects, they can have a potential clinical
application and provide further insight into the pathogenesis
of AD. The evaluation of A2AR expression in the periphery
could be a valuable means to diﬀerentiate mcd-MCI and a-
MCI subjects. Also, it could be hypothesized that the overall
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risk of developing AD is governed by a multifactorial “sus-
ceptibility profile” related not only to gene variants but also
to alterations in the signalling pathway of molecules, such as
adenosine, that play a key role in neuroinflammation.
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